Further genetic alterations in ATRX, TP53, PTEN, EGFR, RB1 NF1, ERBB2, PIK3R1, and PIK3CA are now taken into consideration to guide glioma classification and diagnosis, as well as to program individualized treatments for the distinct molecular subtypes, Figure 1. This evidence concerns the gene ERBB2 and central nervous system cancer.